BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma

Clinical Biochemistry

Volumn 30, Issue 5, 1997, Pages 425-432

  Lianidou, Evriklia S ^a,c   Melegos, Dimitrios N ^a   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

BRCA1; Cancer susceptibility genes; Familial breast cancer; Ovarian cancer; Prostate cancer; Seminal plasma components

Indexed keywords

EPITOPE; GENE PRODUCT; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; FEMALE; FLUOROMETRY; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MALE; MALE GENITAL TRACT CANCER; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; SEMINAL PLASMA; TUMOR SUPPRESSOR GENE;

BINDING, COMPETITIVE; BRCA1 PROTEIN; CROSS REACTIONS; EPITOPES; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOASSAY; MALE; PROTEINS; SEMEN;

EID: 0031194376     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(97)00042-8     Document Type: Article

References (26)

1. 1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903.
2. 2. Miki Y, Swensen J, Shattuck-Eidens, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA-1. Science 1994; 266: 66-71.
3. 3. Futreal PA, Liu Q, Shattuck-Eidens, et al. BRCA-1 mutations in primary breast and ovarian carcinomas. Science 1994; 266: 120-122.
4. 4. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA-2. Nature 1995; 378: 789-792.
5. 5. Narod SA, Ford D, Devukee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995; 56: 254-264.
6. 6. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer. Results from 214 families. Am J Hum Genet 1993; 52: 678-701.
7. 7. Von Arnim AG, Deng XW. Ring finger motif of Arabidopsis thaliana COPI defines a new class of zinc-binding domain. J Biol Chem 1993; 268: 19626-19631.
8. 8. Lovering R, Hanson IM, Borden KLB, et al. Identification and preliminary characterization of a protein motif related to the zinc finger. Proc Natl Acad Sci USA 1993; 90: 2112-2116.
9. 9. Goldgar DE, Reilly PR. A common BRCA-1 mutation in the Ashkenazim. Nat Gen 1995; 11: 113-4.
10. 10. Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA-1 185de1AG mutation is approximately 1% in Ashkenazi Jewish individuals. Nat Gen 1995; 11: 198-200.
11. 11. Jensen RA, Thompson ME, Jetton TL, et al. BRCA1 is secreted and exhibits properties of a granin. Nat Gen 1996; 12: 303-308.
12. 12. Holt JT, Thompson ME, Szabo C, et al. Growth retardation and tumour inhibition by BRCA1. Nat Gen 1996; 12: 298-302.
13. 13. Bradley A, Sharan SK. BRCA-1 products: antibody specificity, functional motifs and secreted tumor suppressors. Nat Gen 1996; 13: 268-269.
14. 14. Chen Y, Chen CF, Riley DJ, et al. Aberrant subcellular localization of BRCA-1 in breast cancer. Science 1995; 270: 789-791.
15. 15. Scully R, Ganesan S, Brown M, et al. Location of BRCA1 in human breast and ovarian cancer cells. Science 1996; 272: 123-125.
16. 16. Anonymous. Meeting to sort out BRCA-1 confusion. Science 1996; 272: 799.
17. 17. Various authors. Nat Gen 1996; 13: 264-272.
18. 18. Steeg PS. Granin expectations in breast cancer? Nat Gen 1996; 12: 223-225.
19. 19. Diamandis EP, Christopoulos TK (Eds.) Immunoassay. San Diego, CA: Academic Press, 1996.
20. 20. Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 1991; 37: 625-636.
21. 21. Hassapoglidou S, Diamandis EP, Sutherland DJA. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 1993; 8: 1501-1509.
22. 22. Christopoulos TK, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992; 64: 342-346.
23. 23. Diamandis EP, Yu H. New biological functions of prostate specific antigen? J Clin Endocrinol Metab 1995; 80: 1515-1517.
24. 24. Sauter ER, Daly M, Lenahan K, et al. Prostate specific antigen in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996; 5: 967-970.
25. 25. Yu H, Giai M, Diamandis EP, et al. Prostate specific antigen is a new favourable prognostic indicator for women with breast cancer. Cancer Res 1995; 55: 2104-2110.
26. 26. Diamandis EP. BRCA1 protein products: antibody specificity, functional motifs and secreted tumour suppressors. Nat Gen 1996; 13: 268.